Open-label placebo reduces fatigue in cancer survivors: a randomized trial
Cancer-related fatigue (CRF) is a common and challenging late effect for many cancer survivors. Clinical trials demonstrate robust placebo effects on CRF in blinded trials. Recently, open-label placebo (OLP) has been shown to improve a variety of symptoms in other populations. We conducted a randomized controlled trial to investigate the effect of OLP on CRF in cancer survivors, and to explore biologic and psychological correlates of placebo efficacy.
Forty cancer survivors (92.5% female; mean age 47.3 years) were randomized to OLP or no treatment control. OLP participants were prescribed two placebo tablets twice daily, for 3 weeks. All participants completed assessments at Baseline, Day 8, and Day 22. The primary endpoint was change in CRF (FACIT-F), and secondary outcomes included exercise frequency, mood, and quality of life. We examined whether personality characteristics or a genetic variation important in dopamine catabolism (catechol-O-methyltransferase; COMT) affected the placebo response.
The OLP group reported significantly improved CRF at both Day 8 (p = 0.005) and Day 22 (p = .02), while the control group did not (ps > .05). CRF improvement differed by COMT genotype, but was not associated with personality characteristics. Marginal improvements were noted in the placebo group for some secondary outcomes (exercise frequency and quality of life), but not in the control group.
Results demonstrate that even when administered openly, placebos improve CRF in cancer survivors and dopaminergic systems may be associated with this response. This novel research has meaningful implications for the use of OLP in symptom management for cancer survivors.
KeywordsOpen-label placebo Cancer-related fatigue, cancer survivors Genetics Quality of life
The authors thank Ted J. Kaptchuk, John M. Kelley, and Irving Kirsch for their valuable consultation.
This study was funded by the Foundation for the Science of the Therapeutic Encounter.
Compliance with ethical standards
Study procedures were approved by the hospital IRB and registered in the clinicaltrials.gov (NCT no. 02452710). All participants gave a written consent.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 2.Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 32(17):1840–1850. https://doi.org/10.1200/JCO.2013.53.4495 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society’s Studies of Cancer Survivors. Cancer 117(12):2779–2790. https://doi.org/10.1002/cncr.26146 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Howell D, Oliver TK, Keller-Olaman S, Davidson J, Garland S, Samuels C, Savard J, Harris C, Aubin M, Olson K, Sussman J, Macfarlane J, Taylor C, Sleep Disturbance Expert Panel on behalf of the Cancer Journey Advisory Group of the Canadian Partnership Against C (2013) A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer. Support Care Cancer 21(10):2695–2706. https://doi.org/10.1007/s00520-013-1823-6 CrossRefPubMedGoogle Scholar
- 12.Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, O’Brien M, Stone P, Benepal T, Bates N, Wee B (2014) Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol 32(18):1882–1888. https://doi.org/10.1200/JCO.2013.54.4346 CrossRefPubMedGoogle Scholar
- 13.Bruera E, Yennurajalingam S, Palmer JL, Perez-Cruz PE, Frisbee-Hume S, Allo JA, Williams JL, Cohen MZ (2013) Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol 31(19):2421–2427. https://doi.org/10.1200/JCO.2012.45.3696 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ (2012) Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 7(10):e48135. https://doi.org/10.1371/journal.pone.0048135 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Petrie KJ, Rief W (2018) Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol. https://doi.org/10.1146/annurev-psych-010418-102907
- 30.Ware J (1993) SF-36 health survey: manual and interpretation guide. The Health Institute, BostonGoogle Scholar
- 32.Godin G, Shephard RJ (1985) A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 10(3):141–146Google Scholar
- 33.Paulhus DL (1998) Paulhus deception scales (PDS): balanced inventory of desirable responding-7 user’s manual. Multi-Health Systems, Inc., North TonawandaGoogle Scholar
- 35.Carver CS, Smith RG, Antoni MH, Petronis VM, Weiss S, Derhagopian RP (2005) Optimistic personality and psychosocial well-being during treatment predict psychosocial well-being among long-term survivors of breast cancer. Health Psychol 24(5):508–516. https://doi.org/10.1037/0278-622.214.171.1248 CrossRefPubMedGoogle Scholar